Obesity Clinical Trial
Official title:
Banded Sleeve Gastrectomy Versus Banded Ring Gastric Bypass in Morbidly Obese Patients: a Prospective Controlled Trial.
Obesity is a multifactorial disease that affects millions of people worldwide. It is the main
independent risk factor for developing type 2 diabetes mellitus (T2DM). Most patients with
T2DM and glucose intolerance (GI) are overweight, a condition known as diabesity. In patients
with the most severe form of obesity, i.e., morbid obesity, the likelihood of developing
diseases associated with obesity is increased.
The investigators currently know that bariatric surgery provides sustained weight loss and
well-documented remission of T2DM. Patients who undergo bariatric surgery show long-term
reduced mortality from coronary artery disease, cancer and diabetes; 136 lives are saved per
10,000 surgical procedures performed. Bariatric surgery is a relatively safe procedure that
is becoming increasingly well-accepted; in 2007, approximately 170,000 bariatric procedures
were performed in the USA. Currently, bariatric surgery is the most effective choice of
treatment of morbidly obese patients with diabetes.
The surgical procedures that are currently performed to treat morbid obesity are divided into
two main groups: gastric restrictive procedures and combination procedures; the latter
combine gastric restriction and malabsorption. The roux-en-Y gastric bypass (RYGB) is the
combination procedure most frequently performed, whereas sleeve gastrectomy (SG) is an
emerging restrictive procedure. SG can be performed as the first of a two-stage operation in
patients at high risk of death, or as a definitive surgical procedure. It has shown good
results with regard to weight loss and glycemic control in various studies. The potential
advantages of SG include lower probability of vitamin and mineral deficiencies because this
procedure has no malabsorptive component; access to the entire intestinal tract; no need for
a subcutaneous access port or adjustments; absence of dumping syndrome and lower probability
of intestinal obstruction. In addition, SG can be performed in patients who have inflammatory
bowel disease or who have undergone bowel surgery, and it can be easily converted into RYGB.
Both SG and RYGB can be performed with or without the placement of a Silastic® ring.
The metabolic control achieved with bariatric procedures has been demonstrated and reproduced
in various medical centers worldwide. Metabolic control can be achieved with gastric
restrictive procedures such as vertical banded gastroplasty, adjustable gastric banding and,
more recently, SG. However, it has been shown that glucose homeostasis is affected by various
intestinal mechanisms observed exclusively in procedures that include a malabsorptive
element, such as RYGB.
A systematic review of 22,094 cases of morbidly obese patients submitted to bariatric surgery
has shown that resolution of T2DM was achieved in 76.8% of the cases, improvement being
achieved in 86% of cases. Among the criteria used to diagnose metabolic syndrome, fasting
glucose levels are the first to return to normal in patients submitted to Silastic® ring
gastric bypass (SRGB), a modification of the traditional RYGB which consists in adding a
Silastic® ring to the gastric bypass operation. Normoglycemia after bariatric procedures, as
well as diabesity itself, is multifactorial. Normoglycemia is observed as a result of dietary
control, decreased plasma levels of ghrelin, weight loss and reduction of body fat, as well
as of the release of gastrointestinal hormones that interfere with the function of pancreatic
β cells (incretins).
The main purpose of this study was to compare the weight loss of morbidly obese patients
submitted to either a Silastic® ring sleeve gastrectomy (SRSG) or an SRGB, as well as to
compare the effects of both procedures on glucose homeostasis in morbidly obese patients.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
| Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
| Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
| Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
| Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
| Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
| Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
| Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
| Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
| Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
| Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
| Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
| Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
| Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
| Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |